Welcome to our dedicated page for DECOY THERAPEUTICS news (Ticker: DCOY), a resource for investors and traders seeking the latest updates and insights on DECOY THERAPEUTICS stock.
Decoy Therapeutics Inc. develops preclinical peptide conjugate therapeutics built around Designable Multi-Antivirals, or D-MAVs, and its proprietary IMP3ACT platform. Company news centers on AI-enabled peptide design, rapid synthesis and manufacturing, respiratory-virus programs, and scientific presentations tied to pan-coronavirus and broad antiviral discovery efforts.
Recurring updates also include computational biology collaborations, non-dilutive program support, investor communications, capital-market actions, and Nasdaq listing-compliance matters. The company's public updates frame Decoy as a preclinical biotechnology issuer focused on respiratory viruses, with earlier company materials also referencing GI cancer pipeline work.
Decoy Therapeutics (Nasdaq:DCOY) reported that a lead Designable Multi-Antiviral (D-MAV™) candidate showed in vitro activity against wild-type Ebola Zaire virus in studies conducted at Texas Biomedical Research Institute. The same candidate, originally engineered on the IMP3ACT™ platform to block coronavirus entry with nanomolar to picomolar activity across known coronavirus strains, also demonstrated in vitro activity against Lassa fever virus.
According to Decoy Therapeutics, these results support its founding premise that a single drug targeting shared class I viral fusion machinery can inhibit multiple viral families. The company has launched an exploratory program to design new D-MAVs against filoviruses, including Ebola and Marburg, and arenaviruses, as part of broader pandemic preparedness efforts while maintaining its primary focus on respiratory virus programs.
Decoy Therapeutics (Nasdaq: DCOY) announced that stockholders elected Patricia Gauthier, MBA, LL.B., as a Class II director at the 2026 Annual Meeting of Stockholders held on July 14, 2026. She will serve alongside Class II directors Rick Pierce and Jon Lieber, who were re-elected.
Gauthier is Senior Vice President, Regional Head for Australia, Canada and the United Kingdom at Moderna, and previously led Moderna Canada, supporting delivery of over 50 million COVID-19 vaccine doses and a Canadian biomanufacturing partnership. She earlier held senior roles at GSK and began her career as a lawyer.
Decoy Therapeutics (NASDAQ:DCOY) entered a securities purchase agreement with a single healthcare-focused institutional investor for a private investment in public equity of up to $21 million in potential gross proceeds.
The PIPE provides $3.5 million upfront at $5.91 per share, plus milestone-based Series A, B and C warrants tied to Phase 1 and Phase 2a clinical trial milestones in Europe and the UK.
Decoy Therapeutics (Nasdaq:DCOY) announced that CEO Rick Pierce will speak at hVIVO’s Capital Markets Day on June 11, 2026, in London. He will discuss early clinical development, the role of human challenge trials, and Decoy’s AI-enabled D-MAV antiviral pipeline, which is aiming for first clinical entry in 2027.
Decoy Therapeutics (Nasdaq:DCOY) nominated global biopharma executive Patricia Gauthier as a Class II director, with a shareholder vote planned at the 2026 Annual Meeting on July 14, 2026.
Gauthier brings leadership experience from Moderna and GSK across vaccines, commercialization and national health security partnerships.
Decoy Therapeutics (Nasdaq:DCOY) entered a strategic collaboration with hVIVO to advance its lead Designable Multi-Antiviral (D-MAV) candidate into Phase 1 and Phase 2a human proof-of-concept studies.
The partnership covers translational modeling, CMC, regulatory strategy, and documentation to support EMA, MHRA, FDA filings and future IND/CTA submissions for multi-virus respiratory antivirals discovered on the AI-enabled IMP³ACT platform.
Decoy Therapeutics (Nasdaq:DCOY), a clinical-stage biotech developing Designable Multi-Antivirals (D-MAVs™), appointed Brad L. Pentelute, Ph.D., MIT Professor of Chemistry and company co-founder, as Chair of its Scientific Advisory Board.
He will help guide Decoy's AI-enabled IMP3ACT™ peptide conjugate platform and multi-antiviral pipeline as programs advance toward clinical development.
Decoy Therapeutics (Nasdaq: DCOY) will present at two Boston peptide therapeutics conferences the week of April 27, 2026. Executives and advisors will discuss computational peptide design, peptide conjugate antivirals, and share new preclinical D-MAV data. The company highlighted a Quantori partnership and its IMP3ACT platform supporting pan-coronavirus and tripledemic programs.
Decoy Therapeutics (Nasdaq: DCOY) said it has accelerated execution across strategy, science and capital markets, advancing its AI-enabled IMP³ACT platform and D-MAV antiviral pipeline toward clinical development.
Key updates include an AI partnership with Quantori + Google Cloud (25–100x compute), a Gates Foundation global access commitment, non-dilutive funding, and a Phase 1 targeted in 2027.
Decoy Therapeutics (Nasdaq: DCOY) will host a Virtual Investor Closing Bell event on Thursday, April 9, 2026 at 4:00 PM ET featuring CEO Rick Pierce.
Mr. Pierce will provide a corporate overview and business outlook for 2026, take live investor questions, and a replay will be available two hours after the presentation for 90 days on the company investor events page.